Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Free Cash Flow (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Free Cash Flow for 4 consecutive years, with -$5.2 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 91.82% to -$5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$167.0 million through Dec 2025, up 37.4% year-over-year, with the annual reading at -$167.0 million for FY2025, 37.4% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$5.2 million at Phathom Pharmaceuticals, up from -$14.1 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$5.2 million in Q4 2025, with the low at -$84.9 million in Q1 2025.
  • Average Free Cash Flow over 4 years is -$44.9 million, with a median of -$41.6 million recorded in 2022.
  • The sharpest move saw Free Cash Flow tumbled 218.34% in 2024, then skyrocketed 91.82% in 2025.
  • Over 4 years, Free Cash Flow stood at -$40.6 million in 2022, then dropped by 5.19% to -$42.7 million in 2023, then plummeted by 48.48% to -$63.3 million in 2024, then surged by 91.82% to -$5.2 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$5.2 million, -$14.1 million, and -$62.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.